Bridge City Capital LLC Purchases 99,227 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Bridge City Capital LLC increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 72.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 235,485 shares of the company’s stock after purchasing an additional 99,227 shares during the period. Amphastar Pharmaceuticals comprises about 1.9% of Bridge City Capital LLC’s investment portfolio, making the stock its 11th largest position. Bridge City Capital LLC owned about 0.51% of Amphastar Pharmaceuticals worth $6,306,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Marshall Wace LLP grew its position in Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock valued at $33,134,000 after acquiring an additional 363,216 shares during the period. Corient IA LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $201,000. Rafferty Asset Management LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $206,000. State Street Corp grew its position in Amphastar Pharmaceuticals by 2.1% in the fourth quarter. State Street Corp now owns 1,531,786 shares of the company’s stock valued at $41,021,000 after acquiring an additional 31,044 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Amphastar Pharmaceuticals by 1.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 55,232 shares of the company’s stock valued at $1,479,000 after acquiring an additional 897 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Trading Down 2.1%

Shares of AMPH opened at $20.09 on Friday. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $31.26. The firm has a market capitalization of $885.83 million, a PE ratio of 12.10, a price-to-earnings-growth ratio of 3.95 and a beta of 0.91. The stock’s fifty day simple moving average is $20.08 and its 200-day simple moving average is $23.39.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The firm had revenue of $171.17 million for the quarter, compared to analyst estimates of $173.46 million. As a group, research analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Barclays lowered their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, June 3rd. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th. Weiss Ratings lowered Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Seven investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of “Reduce” and an average target price of $24.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.